Mizuho cuts Boston Scientific stock target from USD 60 to USD 55

Published on 10/15/2026 at 11:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 7.50 percent to USD 5.44 billion in the second quarter. Boston Scientific stock costs EUR 38.78 on October 15, 2026, 1.17 percent above Xetra close.

Targets and earnings dates

Mizuho Securities cut its target from USD 60.00 to USD 55.00 on October 13, 2026.
Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year.
Boston Scientific stock trades at EUR 38.78 at 11:03 a.m. CEST at Lang & Schwarz on October 15, 2026, 1.17 percent above the Xetra close of October 14, 2026.
Boston Scientific is scheduled to report third-quarter results on October 28, 2026.

Pop-Art-Comic-Szene: Bauarbeiter errichten einen Glas-Büroturm, REIT-Sprechblase, Halbton-Punkte — Boston Properties US1011371077 als farbenfroher Pop-Art-Comic zeigt Bauarbeiter beim Errichten eines Büro-Glasturms, Illustration mit AI erstellt.

Boston Scientific (ISIN US1011371077) stock trades at EUR 38.78 at Lang & Schwarz on October 15, 2026, 1.17 percent above the Xetra close of October 14, 2026 at EUR 38.33. Mizuho Securities cut its Boston Scientific target from USD 60.00 to USD 55.00 on October 13, 2026, according to Gekko. The cut leaves the upcoming earnings report as the next major test for the medical-device maker.

Targets reflect device pressure

The target reduction followed concerns about competition for Boston Scientific's WATCHMAN heart implant and pressure in electrophysiology. Bernstein SocGen Group had already lowered its target from USD 60.00 to USD 54.00 on October 5, 2026, while keeping an Outperform rating, Investing.com reported. The competing Amulet 360 device was cited as a risk to WATCHMAN market share.

Three events reset expectations

On July 29, 2026, Boston Scientific reported second-quarter revenue of USD 5.44 billion, up 7.50 percent year over year, and adjusted earnings per share of USD 0.86. On October 5, 2026, Bernstein cut its target to USD 54.00 from USD 60.00. On October 13, 2026, Mizuho cut its target to USD 55.00 from USD 60.00, according to Gekko.

What comes next for results?

Boston Scientific is scheduled to report third-quarter results before the US market opens on October 28, 2026, according to Yahoo Finance. Analysts cited in the preview expect earnings of USD 0.76 per share, compared with USD 0.75 per share in the year-ago quarter. That comparison puts the reporting date ahead of a forecast for modest earnings growth, while the July guidance reset remains central to the debate.

Stock trades above the Xetra close

Boston Scientific's primary listing is on the NYSE, where the stock closed at USD 43.31 on October 13, 2026. The company reported USD 5.44 billion in second-quarter revenue and USD 907.00 million in net income attributable to common shareholders for the period ended June 30, 2026.

Boston Scientific stock was trading at EUR 38.78 at Lang & Schwarz on October 15, 2026 at 11:03 a.m. CEST, 1.17 percent above the Xetra close of October 14, 2026 at EUR 38.33. The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.